CFO
COLL icon

Callan Family Office’s Collegium Pharmaceutical COLL Stock Holding History

Callan Family Office’s Portfolio COLL Stock Details COLL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$247K Sell
6,824
-1,264
-16% -$43.2K ﹤0.01% 1068
2026
Q1 		$267K Buy
8,088
+17
+0.2% +$720 0.01% 969
2025
Q4 		$374K Buy
+8,071
New +$338K 0.01% 867

Other funds holding COLL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Callan Family Office's COLL Position: Q2 2026 in Review

Callan Family Office reduced its Collegium Pharmaceutical (COLL) stake by 16% in Q2 2026, selling an estimated $43.2K and leaving 6,824 shares worth $247K. The position accounts for ﹤0.01% of the portfolio, ranked #1068.

Callan Family Office first reported a position in COLL in Q4 2025 and has held it in 3 quarters since. The position peaked at $374K in Q4 2025. 279 funds tracked by Wall St. Rank hold COLL as of Q2 2026.

  • Callan Family Office held 6,824 shares of Collegium Pharmaceutical worth $247K as of Q2 2026.
  • Callan Family Office sold 1,264 Collegium Pharmaceutical shares in Q2 2026, an estimated $43.2K.
  • Collegium Pharmaceutical made up ﹤0.01% of Callan Family Office's portfolio in Q2 2026, its #1068 holding.
  • Callan Family Office first reported a position in Collegium Pharmaceutical in Q4 2025 and has held it in 3 quarters since.
  • Callan Family Office's Collegium Pharmaceutical position peaked at $374K in Q4 2025.
  • 279 funds tracked by Wall St. Rank held Collegium Pharmaceutical as of Q2 2026.

Based on Callan Family Office's 13F filing for Q2 2026, filed 11 Aug 2026.